Quality of reporting of drug exposure in pharmacoepidemiological studies
| Autor: | Anthonius de Boer, Kim Luijken, Mirjam Hempenius, Rolf H.H. Groenwold, Olaf H. Klungel, Helga Gardarsdottir |
|---|---|
| Přispěvatelé: | Lyfjafræðideild (HÍ), Faculty of Pharmaceutical Sciences (UI), Heilbrigðisvísindasvið (HÍ), School of Health Sciences (UI), Háskóli Íslands, University of Iceland, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology |
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Drug
medicine.medical_specialty drug exposure pharmacoepidemiology Lyfjafræði Epidemiology Drug exposure media_common.quotation_subject Guidelines as Topic 030226 pharmacology & pharmacy Health data 03 medical and health sciences 0302 clinical medicine Drug Therapy systematic review Original Reports medicine Humans Original Report Pharmacology (medical) Quality (business) 030212 general & internal medicine media_common Exposure assessment reporting Faraldsfræði business.industry Pharmacoepidemiology Reproducibility of Results Guideline Observational Studies as Topic Reporting Research Design Emergency medicine Systematic review Observational study business |
| Zdroj: | Pharmacoepidemiology & Drug Safety, 29(9), 1141-1150. WILEY Pharmacoepidemiology and Drug Safety, 29(9), 1141. John Wiley and Sons Ltd Pharmacoepidemiology and Drug Safety |
| ISSN: | 1053-8569 |
| DOI: | 10.1002/pds.5020 |
| Popis: | Publisher's version (útgefin grein) Purpose: Exposure definitions vary across pharmacoepidemiological studies. Therefore, transparent reporting of exposure definitions is important for interpretation of published study results. We aimed to assess the quality of reporting of exposure to identify where improvement may be needed. Method: We systematically reviewed observational pharmacoepidemiological studies that used routinely collected health data, published in 2017 in six pharmacoepidemiological journals. Reporting of exposure was scored using 11 items of the ISPE-ISPOR guideline on reporting of pharmacoepidemiological studies. Results: Of the 91 studies included, all studies reported the type of exposure (100%), while most reported the exposure risk window (85%) and the exposure assessment window (98%). Operationalization of the exposure window was described infrequently: 16% (14/90) of the studies explicitly reported the presence or absence of an induction period if applicable, 11% (5/47), and 35% (17/49) reported how stockpiling and gaps between exposure episodes were handled, respectively, and 35% (17/49) explicitly mentioned the exposure extension. Switching/add-on was reported in 62% (50/81). How switching between drugs was dealt with and specific drug codes were reported in 52 (57%) and 24 (26%) studies, respectively. Conclusion: Publications of pharmacoepidemiological studies frequently reported the type of exposure, the exposure risk window, and the exposure assessment window. However, more details on exposure assessment are needed, especially when it concerns the operationalization of the exposure risk window (eg, the presence or absence of an induction period or exposure extension, handling of stockpiling and gaps, and specific codes), to allow for correct interpretation, reproducibility, and assessment of validity. RHHG was funded by the Netherlands Organization for Scientific Research (ZonMW‐Vidi project 917.16.430) and an LUMC fellowship. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text